How many institutions held SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value in Q1 2021?

99 institutional investors reported SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value for Q1 2021. Use the holders table for investor-level position and value details.

Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS)

Q: What does CUSIP 87184Q107 represent in this 13F holders report?

CUSIP 87184Q107 is the security identifier for SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value used to aggregate holder disclosures.

CUSIP: 87184Q107

Q1 2021 13F Holders as of 31 Mar 2021

Type / Class: Equity / Common Stock, $0.001 par value
Shares outstanding: 27,995,500
Total 13F shares: 60,879,549
Share change: +7,225,913
Total reported value: $453,765,087
Put/Call ratio: 179%
Price per share: $7.48
Number of holders: 99
Value change: +$51,303,227
Number of buys: 57
Number of sells: 40

Quarterly Holders Quick Answers

What is CUSIP 87184Q107?
CUSIP 87184Q107 identifies SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2021
Previous quarter: Q4 2020

Recent filing periods for CUSIP 87184Q107:

Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021

Top shareholders of SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ARK Investment Management LLC	13F	Company	32%	9,041,321	$98,098,000	—	31 Dec 2020	13F
FMR LLC	13F	Company	24%	6,640,835	$72,053,000	—	31 Dec 2020	13F
Bain Capital Life Sciences Investors, LLC	13F	Company	21%	5,785,036	$62,768,000	—	31 Dec 2020	13F
Amova Asset Management Americas, Inc.	13F	Company	16%	4,381,992	$47,545,000	—	31 Dec 2020	13F
Sumitomo Mitsui Trust Group, Inc.	13F	Company	16%	4,381,992	$47,545,000	—	31 Dec 2020	13F
BlackRock Finance, Inc.	13F	Company	12%	3,325,560	$36,082,000	—	31 Dec 2020	13F
Ally Bridge Group (NY) LLC	13F	Company	9.4%	2,642,500	$28,671,000	—	31 Dec 2020	13F
VANGUARD GROUP INC	13F	Company	7.3%	2,044,704	$22,186,000	—	31 Dec 2020	13F
Samsara BioCapital, LLC	13F	Company	7.8%	2,189,199	$21,837,000	—	31 Dec 2020	13F
Omega Fund Management, LLC	13F	Company	5.6%	1,562,500	$16,953,000	—	31 Dec 2020	13F
ORBIMED ADVISORS LLC	13F	Company	5.6%	1,562,500	$16,953,000	—	31 Dec 2020	13F
EcoR1 Capital, LLC	13F	Company	3.6%	1,000,000	$10,850,000	—	31 Dec 2020	13F
Artal Group S.A.	13F	Company	2.7%	750,000	$8,138,000	—	31 Dec 2020	13F
JPMORGAN CHASE & CO	13F	Company	2.6%	735,872	$7,984,000	—	31 Dec 2020	13F
STATE STREET CORP	13F	Company	2.6%	726,939	$7,887,000	—	31 Dec 2020	13F
BAKER BROS. ADVISORS LP	13F	Company	2.5%	690,167	$7,488,000	—	31 Dec 2020	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	2.1%	590,102	$6,402,000	—	31 Dec 2020	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	1.8%	505,079	$5,480,000	—	31 Dec 2020	13F
NORTHERN TRUST CORP	13F	Company	1.6%	451,788	$4,902,000	—	31 Dec 2020	13F
Portolan Capital Management, LLC	13F	Company	1.4%	381,919	$4,144,000	—	31 Dec 2020	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	1.4%	380,266	$4,126,000	—	31 Dec 2020	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.87%	242,946	$2,636,000	—	31 Dec 2020	13F
D. E. Shaw & Co., Inc.	13F	Company	0.83%	233,687	$2,536,000	—	31 Dec 2020	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.82%	230,800	$2,504,000	—	31 Dec 2020	13F
Redmile Group, LLC	13F	Company	0.76%	212,291	$2,303,000	—	31 Dec 2020	13F
Capital Impact Advisors, LLC	13F	Company	0.6%	168,600	$1,829,000	—	31 Dec 2020	13F
Nuveen Asset Management, LLC	13F	Company	0.52%	144,412	$1,566,000	—	31 Dec 2020	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.5%	139,034	$1,509,000	—	31 Dec 2020	13F
Bank of New York Mellon Corp	13F	Company	0.49%	136,136	$1,477,000	—	31 Dec 2020	13F
CITIGROUP INC	13F	Company	0.46%	129,003	$1,400,000	—	31 Dec 2020	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.44%	122,600	$1,330,000	—	31 Dec 2020	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.42%	117,882	$1,279,000	—	31 Dec 2020	13F
LOS ANGELES CAPITAL MANAGEMENT LLC	13F	Company	0.41%	115,326	$1,251,000	—	31 Dec 2020	13F
CITADEL ADVISORS LLC	13F	Company	0.37%	104,277	$1,131,000	—	31 Dec 2020	13F
Ikarian Capital, LLC	13F	Company	0.36%	100,000	$1,085,000	—	31 Dec 2020	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.35%	98,082	$1,065,000	—	31 Dec 2020	13F
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	13F	Company	0.33%	93,257	$1,012,000	—	31 Dec 2020	13F
STATE OF WISCONSIN INVESTMENT BOARD	13F	Company	0.32%	89,747	$974,000	—	31 Dec 2020	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.31%	86,700	$941,000	—	31 Dec 2020	13F
PDT Partners, LLC	13F	Company	0.3%	84,545	$917,000	—	31 Dec 2020	13F
ALPS ADVISORS INC	13F	Company	0.3%	82,714	$897,000	—	31 Dec 2020	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.27%	76,212	$827,000	—	31 Dec 2020	13F
MORGAN STANLEY	13F	Company	0.27%	75,788	$822,000	—	31 Dec 2020	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0.22%	62,862	$682,000	—	31 Dec 2020	13F
JANE STREET GROUP, LLC	13F	Company	0.2%	55,026	$597,000	—	31 Dec 2020	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.17%	47,593	$516,000	—	31 Dec 2020	13F
RHUMBLINE ADVISERS	13F	Company	0.17%	47,483	$515,000	—	31 Dec 2020	13F
MARSHALL WACE, LLP	13F	Company	0.17%	46,423	$504,000	—	31 Dec 2020	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.16%	44,100	$478,000	—	31 Dec 2020	13F
Cubist Systematic Strategies, LLC	13F	Company	0.14%	38,112	$414,000	—	31 Dec 2020	13F

Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q1 2021

As of 31 Mar 2021, Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) was held by 99 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 60,879,549 shares. The largest 10 holders included FMR LLC, ARK Investment Management LLC, Bain Capital Life Sciences Investors, LLC, Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., BlackRock Inc., Ally Bridge Group (NY) LLC, VANGUARD GROUP INC, Samsara BioCapital, LLC, and ORBIMED ADVISORS LLC. This page lists 99 institutional shareholders reporting positions in this security for the Q1 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2021 vs Q4 2020 Across Filers

Q4 2020 holders

Q1 2021 holders

Holder diff

Investor	Q4 2020 Shares	Q1 2021 Shares	Share Diff	Share Chg %	Q4 2020 Value $	Q1 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.